Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Race Oncology Ltd. ( (AU:RAC) ) has shared an update.
Race Oncology Ltd has received approval from the Republic of Korea’s Ministry of Food and Drug Safety for its Investigational New Drug application to conduct a Phase 1 clinical trial of RC220 in combination with doxorubicin for solid tumor patients. This approval allows Race Oncology to begin patient recruitment at four sites in South Korea, marking a significant step in its global development strategy and reinforcing the strength of its RC220 data package. The approval aligns with rigorous international regulatory standards, similar to those of the US FDA and EU EMA, and highlights the robust patient recruitment environment in Korea.
More about Race Oncology Ltd.
Race Oncology Ltd is a pharmaceutical company focused on developing innovative cancer therapies. The company is engaged in advancing its primary product, RC220, which is aimed at treating solid tumors.
Average Trading Volume: 234,024
Technical Sentiment Signal: Buy
Current Market Cap: A$535.4M
For an in-depth examination of RAC stock, go to TipRanks’ Overview page.